About ocular therapeutix inc. - OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
OCUL At a Glance
Ocular Therapeutix, Inc.
15 Crosby Drive
Bedford, Massachusetts 01730
| Phone | 1-781-357-4000 | Revenue | 63.72M | |
| Industry | Pharmaceuticals: Major | Net Income | -193,506,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 9.034% | |
| Fiscal Year-end | 12 / 2025 | Employees | 274 | |
| View SEC Filings |
OCUL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 21.21 |
| Price to Book Ratio | 4.272 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.162 |
| Enterprise Value to Sales | 16.246 |
| Total Debt to Enterprise Value | 0.073 |
OCUL Efficiency
| Revenue/Employee | 232,565.693 |
| Income Per Employee | -706,226.277 |
| Receivables Turnover | 1.967 |
| Total Asset Turnover | 0.18 |
OCUL Liquidity
| Current Ratio | 10.664 |
| Quick Ratio | 10.59 |
| Cash Ratio | 9.482 |
OCUL Profitability
| Gross Margin | 91.171 |
| Operating Margin | -269.575 |
| Pretax Margin | -303.667 |
| Net Margin | -303.667 |
| Return on Assets | -54.509 |
| Return on Equity | -95.212 |
| Return on Total Capital | -49.474 |
| Return on Invested Capital | -68.848 |
OCUL Capital Structure
| Total Debt to Total Equity | 24.032 |
| Total Debt to Total Capital | 19.376 |
| Total Debt to Total Assets | 16.549 |
| Long-Term Debt to Equity | 23.419 |
| Long-Term Debt to Total Capital | 18.881 |